AIVITA Biomedical

Executive Summary

AIVITA Biomedical is a private, Irvine-based cell and gene therapy company specializing in personalized vaccines for cancer and infectious diseases. Founded in 2016, the company leverages a proprietary platform to design patient-specific immunotherapies, primarily targeting dendritic cell activation. Its lead candidate is a personalized cancer vaccine derived from autologous tumor antigens, currently in Phase 2 trials for glioblastoma and ovarian cancer. While the company has demonstrated proof-of-concept in early studies, it faces significant clinical and regulatory hurdles common to personalized therapies, including manufacturing complexity and scalability. AIVITA has not disclosed total funding or valuation, but its low profile suggests it operates with a lean budget, likely reliant on partnerships or grants. The biotechnology sector remains competitive, but personalized vaccines represent a high-growth area, and AIVITA’s approach offers potential advantages in targeting tumor heterogeneity. Key near-term catalysts include interim data readouts from ongoing Phase 2 trials, potential partnering deals to fund later-stage development, and regulatory milestones such as Fast Track designation. However, the company’s lack of public visibility and limited financial disclosure introduce uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Interim Phase 2 data for personalized glioblastoma vaccine40% success
• Q4 2026FDA Fast Track or Breakthrough Therapy designation for lead candidate60% success
• H1 2027Strategic partnership or collaboration for manufacturing scale-up30% success